Obesity

SYNCHRONIZE-1 evaluated the efficacy and safety of once-weekly survodutide in adults with obesity without diabetes.

A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...

TrialNet researchers assessed whether BMI normalization is associated with reduced risk of stage 3 type 1 diabetes among at-risk patients.

An integrated UK Biobank and preclinical study linked obesity-related metabolic inflammation to PTPN11-mutant myeloid leukemia and found that combined GLP-1R agonism and IL-17A blockade reduced leukemic...

A 2-year trial compared tirzepatide with intensified conventional care in adults with early type 2 diabetes.

Researchers assessed whether GLP-1 exposure was associated with breast cancer incidence among women undergoing screening.

In a phase 3 BWEL substudy, a lifestyle-based weight loss intervention improved patient-reported physical function, global health, social roles and activities, and fatigue in women with stage II-III breast...

April 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

The FDA approved oral GLP-1 orforglipron (Foundayo) for weight management without food or water restrictions.

The FDA has approved insulin icodec-abae as the first once-weekly basal insulin option for glycemic control in adults with type 2 diabetes.